Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have received an average recommendation of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $41.67.

A number of equities analysts have recently commented on the company. Citigroup raised their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen assumed coverage on LENZ Therapeutics in a report on Tuesday. They issued a “buy” rating and a $60.00 price objective on the stock.

Institutional Investors Weigh In On LENZ Therapeutics

A number of large investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in shares of LENZ Therapeutics by 911.0% in the fourth quarter. California State Teachers Retirement System now owns 9,200 shares of the company’s stock valued at $266,000 after buying an additional 8,290 shares in the last quarter. Delta Investment Management LLC acquired a new stake in LENZ Therapeutics during the 4th quarter valued at approximately $555,000. Rafferty Asset Management LLC acquired a new stake in LENZ Therapeutics during the 4th quarter valued at approximately $511,000. Paradigm Biocapital Advisors LP acquired a new stake in LENZ Therapeutics during the 4th quarter valued at approximately $22,243,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in LENZ Therapeutics by 14.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company’s stock valued at $229,000 after purchasing an additional 1,005 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Trading Up 3.1 %

NASDAQ LENZ opened at $26.30 on Tuesday. The business’s 50-day moving average price is $24.09 and its 200 day moving average price is $27.01. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). As a group, research analysts anticipate that LENZ Therapeutics will post -2.18 earnings per share for the current year.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.